Bavarian Nordic A/S - Report on the Results of the Extraordinary General Meeting, held 25 May 2010

In accordance with the agenda an Extraordinary General Meeting of Bavarian
Nordic A/S was held today 25 May 2010 with the following results:

·       The General Assembly adopted the Board of Directors' proposal regarding
the following amendments:

o   Amendments of the Articles of Association in consequence of the new Danish
Companies Act.
o   Introduction of a new Article 5b authorizing the Board of Directors to issue
warrants.
o   Cancellation of Article 5e of the Articles of Association.
o   Cancellation of the quorum requirement in Article 16 of the Articles of
Association.

·       The Board of Directors were given authorization to let the Company
purchase its own shares of company stock in the period up to the next Annual
General Meeting.


Asger Aamund
Chairman of the Board

Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64


About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline is focused in
the three areas; cancer, biodefence and infectious diseases, and includes seven
development programmes. Two programmes are under preparation for Phase III:
PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being
developed under a collaboration agreement with the National Cancer Institute,
and IMVAMUNE®, a third-generation smallpox vaccine is being developed under a
contract with the US government.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
<http://www.bavarian-nordic.com/>

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.


[HUG#1418383]